Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 50.7 1.40% 0.70
SAGE closed up 1.4 percent on Friday, August 7, 2020, on 85 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Aug 10
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical SAGE trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
NR7 Range Contraction 1.40%
Upper Bollinger Band Walk Strength 1.40%
Inside Day Range Contraction 1.40%
Overbought Stochastic Strength 1.40%
Upper Bollinger Band Touch Strength 1.40%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Physical Sciences Drugs Antidepressants Gabaa Receptor Positive Allosteric Modulators Adjunctive Therapy Anticonvulsants Neurosteroids

Is SAGE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 173.755
52 Week Low 25.01
Average Volume 762,730
200-Day Moving Average 63.70
50-Day Moving Average 42.28
20-Day Moving Average 46.47
10-Day Moving Average 47.96
Average True Range 2.13
ADX 28.39
+DI 31.73
-DI 12.68
Chandelier Exit (Long, 3 ATRs ) 45.41
Chandelier Exit (Short, 3 ATRs ) 47.06
Upper Bollinger Band 51.39
Lower Bollinger Band 41.54
Percent B (%b) 0.93
BandWidth 21.21
MACD Line 2.06
MACD Signal Line 1.79
MACD Histogram 0.2704
Fundamentals Value
Market Cap 1.9 Billion
Num Shares 37.4 Million
EPS -6.09
Price-to-Earnings (P/E) Ratio -8.33
Price-to-Sales 0.00
Price-to-Book 8.73
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.97
Resistance 3 (R3) 53.98 52.89 53.43
Resistance 2 (R2) 52.89 52.06 52.89 53.24
Resistance 1 (R1) 51.80 51.55 52.35 51.79 53.06
Pivot Point 50.71 50.71 50.99 50.71 50.71
Support 1 (S1) 49.62 49.88 50.17 49.61 48.34
Support 2 (S2) 48.53 49.37 48.53 48.16
Support 3 (S3) 47.44 48.53 47.98
Support 4 (S4) 47.43